Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study

Anticipatory (prechemotherapy) nausea (AN) is a classic conditioned symptom not responding well to current antiemetics. Minimal work has been done to assess its risk factors and impact on chemotherapy-induced nausea and vomiting (CINV). To evaluate risk factors for AN and assess its impact on CINV d...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pain and symptom management 2016-06, Vol.51 (6), p.987-993
Main Authors: Molassiotis, Alexander, Lee, Paul H., Burke, Thomas A., Dicato, Mario, Gascon, Pere, Roila, Fausto, Aapro, Matti
Format: Article
Language:English
Subjects:
Anticipation, Psychological
Anticipatory nausea
antiemetics
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
cancer
chemotherapy-related nausea and vomiting
Europe
Female
Humans
Likelihood Functions
Logistic Models
Male
Middle Aged
Nausea - epidemiology
Nausea - etiology
Neoplasms - drug therapy
Neoplasms - epidemiology
prechemotherapy nausea
Prospective Studies
Registries
Risk Factors
Vomiting, Anticipatory - epidemiology
Vomiting, Anticipatory - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anticipatory (prechemotherapy) nausea (AN) is a classic conditioned symptom not responding well to current antiemetics. Minimal work has been done to assess its risk factors and impact on chemotherapy-induced nausea and vomiting (CINV). To evaluate risk factors for AN and assess its impact on CINV development. We analyzed data (n = 991) from a prospective observational multisite study in eight European countries over three cycles of chemotherapy. Patient/treatment characteristics were collected before chemotherapy. History of nausea/vomiting (yes/no), patient expectation of CINV (0–100 mm visual analog scale, [VAS]), and prechemotherapy anxiety (0–100 mm VAS) also were collected before chemotherapy. A patient-completed diary during each chemotherapy cycle obtained information on AN in the 24 hours before chemotherapy administration and nausea and vomiting (episodes of vomiting and severity of nausea) daily for five days after administration of chemotherapy (0–100 mm VAS). AN was reported by 8.3%–13.8% of patients, increasing in frequency and intensity over each cycle. Every 1 mm increase in AN on the VAS was significantly associated with 2%–13% of increase in the likelihood of CINV (all P-values
ISSN:0885-3924
1873-6513
DOI:10.1016/j.jpainsymman.2015.12.317